MREO — Mereo BioPharma Income Statement
0.000.00%
Last trade - 00:00
- $504.88m
- $454.36m
- £7.91m
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | 20-F | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 36.5 | 0 | 7.91 |
Cost of Revenue | |||||
Gross Profit | — | — | 18.6 | 0.936 | -4.02 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 38.5 | 37.6 | 57.4 | 43.6 | 40.9 |
Operating Profit | -38.5 | -37.6 | -20.9 | -43.6 | -33 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -41.1 | -166 | 14.2 | -35.1 | -34.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -34.8 | -164 | 12.7 | -33.2 | -33.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -34.8 | -164 | 12.7 | -33.2 | -33.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -34.8 | -164 | 12.7 | -33.2 | -33.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.397 | -0.462 | 0.024 | -0.055 | -0.05 |